Document is current

Article History

Received: 16 December 2019

Accepted: 28 March 2020

First Online: 10 April 2020

Compliance with ethical standards

:

: UC: Grant: Tumorzentrum Dresden, Advisory board: Roche, Astra Zeneca, Honoraria: Roche, Astra Zeneca, Lilly; HJL: advisory board: Amgen, Astra Zeneca, GSK, Lilly, Novartis, Pfizer, Roche, Honoraria: Amgen, Roche, Astra Zeneca, Clovis, GSK, Lilly, Novartis, Pfizer; AB: Advisory board/ honoraria: Roche, Astra Zeneca, Tesaro; PH: Grants: Tesaro, GSK, Boehringer Ingelheim, Medac, Genmab, Astra Zeneca, Roche, Public funding (ASCO, DKH, DFG), Personal fees: Sotio, Tesaro, Stryker, Zai Lab, MSD, Public funding (ASCO, DKH, DFG), Clovis, Immunogen, Astra Zeneca, Roche; SM: Grants: Astra Zeneca, Medac, MSD, PharmaMar, Roche, Tesaro, Teva, Personal fees: Astra Zeneca, Clovis, Medac, MSD, Novartis, PharmaMar, Roche, Sensor Kinesis, Tesaro, Teva; SK: Personal fees: Roche, Astra Zeneca, Tesaro, PharmaMar, Clovis; PW: Grant: Tumorzentrum Dresden, Advisory board/ honoraria: Amgen, Astra Zeneca, MSD, Novartis, Pfizer, PharmaMar, Roche, Teva, Eisei, Clovis, Tesaro; NdG: Personal fees: Astra Zeneca, Roche, Amgen, Clovis, MSD, PharmaMar, Travel expenses: Astra Zeneca, Tesaro; AH: Advisory board: PharmaMar, Promedicis, Pierre Fabre, Roche, Tesaro, Honoraria: Astra Zeneca, Celgene, MedConcept, Med update, Medicultus, Pfizer, Promedicis, Pierre Fabre, Roche, Tesaro, Research grant: Celgene; MGM: Personal fees: Astra Zeneca; AEB: Personal fees: Astra Zeneca, Roche, PharmaMar, Olympus, Clovis, Tesaro, Travel expenses: Astra Zeneca, PharmaMar, Olympus, Tesaro; AdB: Advisory board/ honoraria: Roche, Astra Zeneca, Tesaro, Clovis, Pfizer, Biocad, Genmab, Seattle Genetics, MSD. All other authors declared not to have any conflicts of interest.

: As this is a retrospective study this is not applicable.